View Author
patient study infarction trial event treatment investigator platelet intervention death receptor level group elevation syndrome percutaneou angina pursuit therapy glycoprotein result heart analysis placebo outcome effect ck-mb disease eptifibatide mortality heparin value /ilia baseline 30 days table /iiia lefradafiban glucose incidence inhibition episode stroke blocker ratio artery disease artery inhibitor circulation protocol europe benefit region monitoring difference characteristic blood insulin site investigators america factor hospital pursuit trial reduction population period point complication figure abciximab st-segment variable events committee infusion predictor chapter angioplasty safety prognostic ischemia
10 Most Recent Publications
|
Changes in clinical profile, treatment, and mortality in patients hospitalised for acute myocardial infarction between 1985 and 2008
(Article)
Nauta, S.T. Deckers, J.W. Akkerhuis, K.M. Lenzen, M.J. Simoons, M.L. Domburg, R.T. van |
2011-11-02
|
|
Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients
(Article)
Marcolino, M.S. Boersma, E.R. Clementino, N.C.D. Macedo, A.V. Marx-Neto, A.D. Silva, M.H.C.R. Gelder, T. van Akkerhuis, K.M. Ribeiro, A.L. |
2011-09-01
|
|
Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome
(Article)
Oemrawsingh, R.M. Lenderink, T. Akkerhuis, K.M. Heeschen, C. Baldus, S. Fichtlscherer, S. Hamm, C.W. Simoons, M.L. Boersma, H. |
2011-07-01
|
|
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals
(Article)
Brugts, J.J. Isaacs, A. Remme, W.J. Bertrand, M.E. Ninomiya, T. Harrap, S. Chalmers, J. MacMahon, S. Fox, K. Ferrari, R. Simoons, M.L. Danser, A.H.J. Maat, M.P.M. de Boersma, E.R. Duijn, C.M. van Akkerhuis, K.M. Uitterlinden, A.G. Witteman, J.C.M. Cambien, F. Ceconi, C. |
2011-03-01
|
|
Impact of an alerting clinical decision support system for glucose control on protocol compliance and glycemic control in the intensive cardiac care unit
(Article)
Lipton, J.A. Barendse, R.J. Schinkel, A.F. Akkerhuis, K.M. Simoons, M.L. Sijbrands, E.J.G. |
2011-03-01
|
|
Evaluation of a clinical decision support system for glucose control: Impact of protocol modifications on compliance and achievement of glycemic targets
(Article)
Lipton, J.A. Barendse, R.J. Akkerhuis, K.M. Schinkel, A.F. Simoons, M.L. |
2010-09-01
|
|
Prognostic Significance of QRS Duration in Patients With Suspected Coronary Artery Disease Referred for Noninvasive Evaluation of Myocardial Ischemia
(Article)
Schinkel, A.F. Elhendy, A.A. Cate, F.J. ten Simoons, M.L. Bax, J.J. Poldermans, D. Domburg, R.T. van Biagini, E. Rizzello, V. Veltman, C.E. Kate, G.L. ten Sijbrands, E.J.G. Akkerhuis, K.M. Geleijnse, M.L. |
2009-12-01
|
|
Tailor-made therapy for the prevention of acute coronary syndromes: Future role of biomarkers in risk stratification and disease management
(Article)
Oemrawsingh, R.M. Akkerhuis, K.M. Boersma, H. |
2008-04-01
|
|
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
(Article)
Roe, M.T. Mahaffey, K.W. Lincoff, A.M. Califf, R.M. Topol, E.J. Werf, F.J.J. van de Alexander, J.H. Armstrong, P.W. Kilaru, R. Akkerhuis, K.M. Simoons, M.L. Harrington, R.A. Tardiff, B.E. Granger, C.B. Ohman, E.M. Moliterno, D.J. |
2004-02-01
|
|
Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?
(Article)
Akkerhuis, K.M. Alexander, J.H. Tardiff, B.E. Harrington, R.A. Lincoff, A.M. Simoons, M.L. Boersma, H. |
2002-02-05
|
